Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	9.57M
Revenue (ttm)	n/a
Net Income (ttm)	-12.75M
Shares Out	5.32M
EPS (ttm)	-3.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,995
Open	1.830
Previous Close	1.860
Day's Range	1.770 - 1.940
52-Week Range	1.770 - 11.850
Beta	0.39
Analysts	Strong Buy
Price Target	30.00 (+1,566.67%)
Earnings Date	Nov 15, 2024

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing Nu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: BCLI
• Website: https://www.brainstorm-cell.com

Analyst Forecast

According to one analyst, the rating for BCLI stock is "Strong Buy" and the 12-month stock price forecast is $30.0.

Price Target

$30.0

(1,566.67% upside)

Analyst Consensus: Strong Buy